BR112022013867A2 - Bactérias manipuladas para tratar distúrbios nos quais o oxalato é prejudicial - Google Patents
Bactérias manipuladas para tratar distúrbios nos quais o oxalato é prejudicialInfo
- Publication number
- BR112022013867A2 BR112022013867A2 BR112022013867A BR112022013867A BR112022013867A2 BR 112022013867 A2 BR112022013867 A2 BR 112022013867A2 BR 112022013867 A BR112022013867 A BR 112022013867A BR 112022013867 A BR112022013867 A BR 112022013867A BR 112022013867 A2 BR112022013867 A2 BR 112022013867A2
- Authority
- BR
- Brazil
- Prior art keywords
- oxalate
- harmful
- bacteria
- manipulated
- treat disorders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/93—Ligases (6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/13—Transferases (2.) transferring sulfur containing groups (2.8)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y208/00—Transferases transferring sulfur-containing groups (2.8)
- C12Y208/03—CoA-transferases (2.8.3)
- C12Y208/03016—Formyl-CoA transferase (2.8.3.16)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y401/00—Carbon-carbon lyases (4.1)
- C12Y401/01—Carboxy-lyases (4.1.1)
- C12Y401/01002—Oxalate decarboxylase (4.1.1.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y401/00—Carbon-carbon lyases (4.1)
- C12Y401/01—Carboxy-lyases (4.1.1)
- C12Y401/01008—Oxalyl-CoA decarboxylase (4.1.1.8)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y602/00—Ligases forming carbon-sulfur bonds (6.2)
- C12Y602/01—Acid-Thiol Ligases (6.2.1)
- C12Y602/01008—Oxalate--CoA ligase (6.2.1.8)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062960950P | 2020-01-14 | 2020-01-14 | |
| US202062993301P | 2020-03-23 | 2020-03-23 | |
| US202063028902P | 2020-05-22 | 2020-05-22 | |
| US202063065752P | 2020-08-14 | 2020-08-14 | |
| US202063089758P | 2020-10-09 | 2020-10-09 | |
| US202063091620P | 2020-10-14 | 2020-10-14 | |
| US202063111376P | 2020-11-09 | 2020-11-09 | |
| PCT/US2021/013401 WO2021146397A1 (en) | 2020-01-14 | 2021-01-14 | Bacteria engineered to treat disorders in which oxalate is detrimental |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022013867A2 true BR112022013867A2 (pt) | 2022-09-13 |
Family
ID=76864711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022013867A BR112022013867A2 (pt) | 2020-01-14 | 2021-01-14 | Bactérias manipuladas para tratar distúrbios nos quais o oxalato é prejudicial |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230092431A1 (https=) |
| EP (1) | EP4090343A4 (https=) |
| JP (1) | JP2023511282A (https=) |
| CN (1) | CN115335066A (https=) |
| AU (1) | AU2021207879A1 (https=) |
| BR (1) | BR112022013867A2 (https=) |
| CA (1) | CA3167754A1 (https=) |
| IL (1) | IL294710A (https=) |
| WO (1) | WO2021146397A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3203975A1 (en) | 2020-12-03 | 2022-06-09 | Battelle Memorial Institute | Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery |
| WO2022204406A1 (en) * | 2021-03-24 | 2022-09-29 | Synlogic Operating Company, Inc. | Bacteria engineered to treat disorders in which oxalate is detrimental |
| CA3216359A1 (en) | 2021-04-07 | 2022-10-13 | Battelle Memorial Institute | Rapid design, build, test, and learn technologies for identifying and using non-viral carriers |
| GB202402011D0 (en) | 2024-02-14 | 2024-03-27 | Snipr Biome Aps | A novel type of crispr/cas system |
| AU2024353375A1 (en) | 2023-09-29 | 2026-04-09 | Battelle Memorial Institute | Polymer nanoparticle compositions for in vivo expression of polypeptides |
| WO2025122954A1 (en) | 2023-12-08 | 2025-06-12 | Battelle Memorial Institute | Use of dna origami nanostructures for molecular information based data storage systems |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1309427B1 (it) * | 1999-05-28 | 2002-01-23 | Mendes S U R L | Composizione dietetica o farmaceutica utile per la prevenzione o iltrattamento dell'iperossaluria e suo uso |
| WO2007070052A2 (en) * | 2005-12-14 | 2007-06-21 | Oxthera, Inc. | Pharmaceutical compositions and methods for treating or preventing oxalate-related disease |
| US9283252B2 (en) * | 2008-09-30 | 2016-03-15 | Meiji Co., Ltd. | Lactic acid bacterium having high oxalic acid decomposition ability |
| US11273184B2 (en) * | 2015-08-31 | 2022-03-15 | Synlogic Operating Company, Inc. | Bacteria engineered to treat disorders in which oxalate is detrimental |
| EP3468572B1 (en) * | 2016-06-13 | 2022-03-02 | OxThera Intellectual Property AB | Compositions and methods for the treatment or prevention of oxalate-related disorders |
| CN111655841A (zh) * | 2017-06-21 | 2020-09-11 | 同生运营公司 | 用于治疗紊乱的细菌 |
| JP2020527025A (ja) * | 2017-07-12 | 2020-09-03 | シンロジック オペレーティング カンパニー インコーポレイテッド | 腫瘍細胞において免疫モジュレーターおよび抗がん治療剤を産生するようにプログラムされた微生物 |
| IT201800005355A1 (it) * | 2018-05-14 | 2019-11-14 | Lactobacillus amylovorus SGL 14: attività probiotiche e riduzione dell’ossalato enterico |
-
2021
- 2021-01-14 BR BR112022013867A patent/BR112022013867A2/pt not_active IP Right Cessation
- 2021-01-14 CN CN202180020940.5A patent/CN115335066A/zh active Pending
- 2021-01-14 US US17/792,030 patent/US20230092431A1/en not_active Abandoned
- 2021-01-14 JP JP2022542946A patent/JP2023511282A/ja active Pending
- 2021-01-14 EP EP21741375.6A patent/EP4090343A4/en not_active Withdrawn
- 2021-01-14 AU AU2021207879A patent/AU2021207879A1/en not_active Abandoned
- 2021-01-14 CA CA3167754A patent/CA3167754A1/en active Pending
- 2021-01-14 WO PCT/US2021/013401 patent/WO2021146397A1/en not_active Ceased
- 2021-01-14 IL IL294710A patent/IL294710A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021146397A1 (en) | 2021-07-22 |
| EP4090343A4 (en) | 2024-02-14 |
| JP2023511282A (ja) | 2023-03-17 |
| US20230092431A1 (en) | 2023-03-23 |
| AU2021207879A1 (en) | 2022-09-08 |
| IL294710A (en) | 2022-09-01 |
| CA3167754A1 (en) | 2021-07-22 |
| CN115335066A (zh) | 2022-11-11 |
| EP4090343A1 (en) | 2022-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022013867A2 (pt) | Bactérias manipuladas para tratar distúrbios nos quais o oxalato é prejudicial | |
| BR112022002442A2 (pt) | Terapias de imuno-oncologia com conjugados de il-2 | |
| BR112017013599A2 (pt) | composição farmacêutica, e, método para prevenir, tratar ou melhorar um ou mais sintomas de um tumor maligno associado à mutação de kras. | |
| BR112022004699A2 (pt) | Vs-6063 em combinação com ch5126766 para o tratamento de câncer | |
| BR112020026125A8 (pt) | Compostos oligonucleotídeos superiores ou 5'-cap- trinucleotídeo e seus usos na estabilização de rna, expressão de proteínas e em terapia | |
| BR112020017090A8 (pt) | Imunoterapias relacionadas com microbioma | |
| CO2018012099A2 (es) | Composiciones y métodos para programar células terapéuticas utilizando nanoportadores de ácidos nucleicos dirigidos | |
| BR112022019932A2 (pt) | Composições para saúde metabólica | |
| BR112017021021A2 (pt) | inibidores de indolamina-2,3-dioxigenase para o tratamento de câncer | |
| BR112017024331A2 (pt) | composto, composição farmacêutica, método de tratamento de um humano, métodos para inibir a atividade de uma proteína ido1, o crescimento ou a proliferação de células cancerosas, e a imunossupressão em um paciente, e de tratamento de uma doença, e, uso de um composto | |
| BR112013026494A2 (pt) | composto, composição farmacêutica, método para tratar condição | |
| BR112019024264A2 (pt) | Antimitoscinas: inibidores direcionados da biogênese mitoconcrial para erradicação de células-tronco de câncer | |
| BR112013008881A2 (pt) | métodos e composições para tratamento de hemofilia b | |
| BR112021019262A2 (pt) | Uso de ciclo-his-pro (chp) para prevenir, atenuar ou tratar fibrose | |
| MX2022006364A (es) | Tratamiento genico con apoe. | |
| BR112019003731A2 (pt) | aplicação de pridopidina para tratamento de distonias | |
| BR112012013888A2 (pt) | preparados de combinação com antagonista de citocina e corticosteroide | |
| CO2021002691A2 (es) | Composiciones y métodos para editar el gen hidroxiácido oxidasa 1 (hao1) para tratar la hiperoxaluria primaria tipo 1 (ph1) | |
| BR112014010594A2 (pt) | terapia genética para neuropatia diabética empregando um isoforma do hgf | |
| BR112015003729A2 (pt) | composto de fórmula estrutural i; composição farmacêutica; método de tratamento de uma doença mediada por caminho do hif; método de tratamento de uma doença causada por proliferação anormal de células; e método para alcançar um efeito em um paciente | |
| JOP20180110A1 (ar) | تركيبات وطرق لمعالجة أو الوقاية من اضطرابات متعلقة بأوكسالات | |
| BR112022021827A2 (pt) | Métodos para tratar covid-19 | |
| BR112022011388A2 (pt) | Métodos para tratar ou prevenir asma alérgica administrando um antagonista de il-33 e/ou um antagonista de il-4r | |
| BR112022006016A2 (pt) | Métodos e materiais para tratar neurotoxicidade | |
| BR112014011641A2 (pt) | composto; composição; uso de um composto; método para tratar pelo menos uma doença, distúrbio ou condição selecionada de obesidade, sobrepeso ou distribuição de gordura anormal e condições ou doenças associadas com os mesmos em um sujeito em necessidade do mesmo; método para remodelar tecido adiposo branco para tecido adiposo tipo marrom em um sujeito; método para tratar uma doença, distúrbio ou condição associada com ou se beneficiando da remodelação de tecido adiposo branco para tecido adiposo tipo marrom em um sujeito; e método para reduzir o tecido adiposo branco (wat) em um sujeito em necessidade do mesmo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2862 DE 11/11/2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS. |